Arrowhead Pharmaceuticals (ARWR) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to 0.35.
- Arrowhead Pharmaceuticals' Equity Ratio rose 54055.31% to 0.35 in Q4 2025 from the same period last year, while for Dec 2025 it was 0.35, marking a year-over-year increase of 54055.31%. This contributed to the annual value of 0.36 for FY2025, which is 11678.92% up from last year.
- Latest data reveals that Arrowhead Pharmaceuticals reported Equity Ratio of 0.35 as of Q4 2025, which was up 54055.31% from 0.36 recorded in Q3 2025.
- In the past 5 years, Arrowhead Pharmaceuticals' Equity Ratio ranged from a high of 0.64 in Q1 2022 and a low of 0.06 during Q4 2024
- Over the past 5 years, Arrowhead Pharmaceuticals' median Equity Ratio value was 0.46 (recorded in 2022), while the average stood at 0.45.
- In the last 5 years, Arrowhead Pharmaceuticals' Equity Ratio crashed by 8005.65% in 2024 and then soared by 54055.31% in 2025.
- Arrowhead Pharmaceuticals' Equity Ratio (Quarter) stood at 0.58 in 2021, then decreased by 23.8% to 0.44 in 2022, then tumbled by 37.62% to 0.28 in 2023, then plummeted by 80.06% to 0.06 in 2024, then soared by 540.55% to 0.35 in 2025.
- Its Equity Ratio was 0.35 in Q4 2025, compared to 0.36 in Q3 2025 and 0.38 in Q2 2025.